Zobrazeno 1 - 10
of 429
pro vyhledávání: '"P2Y12 inhibitor"'
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 13, Iss 16 (2024)
Background This study aimed to explore the effect of a P2Y12 inhibitor regimen on the occurrence of postoperative atrial fibrillation (POAF) after off‐pump coronary artery bypass graft surgery in carriers with the cytochrome P450 family 2 subfamily
Externí odkaz:
https://doaj.org/article/4aa5a7b12e6e436cbe7d23c124fd3634
Publikováno v:
Heliyon, Vol 10, Iss 15, Pp e35741- (2024)
Background: A modified antiplatelet therapy approach after percutaneous coronary intervention (PCI), specifically reducing dual antiplatelet therapy (DAPT) duration and transitioning to P2Y12 inhibitor monotherapy, may offer advantages in terms of bl
Externí odkaz:
https://doaj.org/article/d42c3eaf32614b4284847d56dc754490
Autor:
Chien-Lung Huang, Tien-Ping Tsao, Wei-Hsian Yin, Wen-Bin Huang, Hsu-Lung Jen, Chang-Chyi Lin, Chung-Yi Chang, Ching-Hwa Hsu
Publikováno v:
International Journal of Cardiology: Heart & Vasculature, Vol 51, Iss , Pp 101359- (2024)
Potent P2Y12 receptor antagonists have been used widely for patients undergoing percutaneous coronary intervention with different results. Benefits from different regimens various between trials. Randomized controlled trials (RCTs) have restrictive i
Externí odkaz:
https://doaj.org/article/df2b17ff6dfa4589a31e19db5d0b4a65
Publikováno v:
Pharmacogenomics and Personalized Medicine, Vol Volume 16, Pp 973-990 (2023)
Angelo Oliva,1,2 Davide Cao,1,3 Alessandro Spirito,1 Johny Nicolas,1 Brunna Pileggi,1,4 Karim Kamaleldin,1 Birgit Vogel,1 Roxana Mehran1 1The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York City,
Externí odkaz:
https://doaj.org/article/5c73eb0112644f43bc78967d1e99bc76
P2Y12 Receptor Inhibitor for Antiaggregant Therapies: From Molecular Pathway to Clinical Application
Autor:
Francesco Nappi
Publikováno v:
International Journal of Molecular Sciences, Vol 25, Iss 14, p 7575 (2024)
Platelets play a significant role in hemostasis, forming plugs at sites of vascular injury to limit blood loss. However, if platelet activation is not controlled, it can lead to thrombotic events, such as myocardial infarction and stroke. To prevent
Externí odkaz:
https://doaj.org/article/08013b12d86c414fb82d6dccaa702dda
Publikováno v:
Platelets, Vol 34, Iss 1 (2023)
Chronic kidney disease (CKD) is a global health problem and an independent risk factor for cardiovascular morbidity and mortality. Despite evidence-based therapies significantly improving cardiovascular mortality outcomes in the general population an
Externí odkaz:
https://doaj.org/article/da92ef0a269f4f0cabc02b38079133b7
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Yachao Li, Mengjie Lei, Zhigang Zhao, Yanli Yang, Lei An, Jingyao Wang, Xue Sun, Cairong Li, Zengming Xue
Publikováno v:
Frontiers in Cardiovascular Medicine, Vol 10 (2023)
BackgroundThis study aimed to systematically evaluate the effects of different types and doses of pretreatment with P2Y12 inhibitors in patients with non-ST-elevation acute coronary syndrome (NSTE-ACS) undergoing percutaneous coronary intervention (P
Externí odkaz:
https://doaj.org/article/383b3125d8ce49bc9b6a09cb1dbc3da5
Publikováno v:
Frontiers in Cardiovascular Medicine, Vol 10 (2023)
IntroductionIn patients with coronary artery disease (CAD) and chronic kidney disease (CKD) undergoing percutaneous coronary intervention (PCI), whether short-term dual antiplatelet therapy (DAPT) followed by P2Y12 inhibitors confers benefits compare
Externí odkaz:
https://doaj.org/article/2246a6c167fc4103ba80f5e32b531434
Autor:
Jennifer A. Rymer, Zachary K. Wegermann, Lisa A. Kaltenbach, Laura E. Webb, Eric D. Peterson, Tracy Y. Wang
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 12, Iss 12 (2023)
Background Premature discontinuation of P2Y12 inhibitor therapy has been associated with adverse cardiac events, which might be preventable by improving medication persistence. Current risk models have limited ability to predict patients at risk of P
Externí odkaz:
https://doaj.org/article/d273049689e64f5682de662939dbb918